# AstraZeneca’s Lynparza granted FDA priority review for PROpel

- Link: https://www.directorstalkinterviews.com/astrazenecas-lynparza-granted-fda-priority-review-for-propel/4121077752
- Published: 2022-08-16T07:30:17+01:00
- Author: Amilia Stone

**[AstraZeneca plc](https://www.directorstalkinterviews.com/ftse-company/astrazeneca/azn.l)**(
[LON:AZN](https://www.directorstalkinterviews.com/ftse-company/astrazeneca/azn.l))
supplemental New Drug Application (sNDA) for _Lynparza_ (olaparib) in combination
with abiraterone and prednisone or prednisolone has been accepted and granted Priority
Review in the US for the treatment of adult patients with metastatic castration-
resistant prostate cancer (mCRPC).

_Lynparza_ is being jointly developed and commercialised by AstraZeneca and MSD.

The Food and Drug Administration (FDA) grants Priority Review to applications for
medicines that offer significant advantages over available options by demonstrating
safety or efficacy improvements, preventing serious conditions, or enhancing patient
compliance.^(1) The Prescription Drug User Fee Act date, the FDA action date for
their regulatory decision, is anticipated during the fourth quarter of 2022.

In the US, prostate cancer is the second most common cancer in male patients and
is projected to cause approximately 35,000 deaths in 2022.^(2) Overall survival 
for patients with mCRPC is approximately three years in clinical trial settings,
and even shorter in the real world.^(3-6) Approximately half of patients with mCRPC
may receive only one line of active treatment, with diminishing benefit of subsequent
therapies.^(6-11)

> **Susan Galbraith, Executive Vice President, Oncology R&D, AstraZeneca, said: **“
> There remains a critical unmet need among patients diagnosed with metastatic castration-
> resistant prostate cancer, where the prognosis remains poor and treatment options
> are limited. Today’s news is another step towards bringing forward a new, much-
> needed treatment option in this setting. If approved, _Lynparza_ with abiraterone
> will become the first combination of a PARP inhibitor and a new hormonal agent
> for patients with this disease.”

> **Dr. Eliav Barr, Senior Vice President, Head of Global Clinical Development and
> Chief Medical Officer, MSD Research Laboratories, said**: “MSD is committed to
> developing new treatment options for patients with metastatic castration-resistant
> prostate cancer, a complex disease that urgently needs more therapies. We look
> forward to working with the FDA towards the goal of bringing a new option to patients
> with mCRPC with or without HRR gene mutations.”

The sNDA was based on results from the PROpel Phase III trial presented at the 2022
American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium and
later published in NEJM Evidence_._

These results showed _Lynparza_ in combination with abiraterone reduced the risk
of disease progression or death by 34% versus abiraterone alone (based on a hazard
ratio [HR] of 0.66; 95% confidence interval [CI] 0.54-0.81; p<0.0001). Median radiographic
progression-free survival (rPFS) was 24.8 months for _Lynparza_ plus abiraterone
versus 16.6 for abiraterone alone. The safety and tolerability of _Lynparza_ in 
combination with abiraterone was in line with that observed in prior clinical trials
and the known profiles of the individual medicines.^(12)

_Lynparza_ is approved in the US for patients with HRR gene-mutated mCRPC (BRCA-
mutated and other HRR gene mutations) who have progressed following prior treatment
with enzalutamide or abiraterone; and in the EU, Japan and China for patients with
BRCA-mutated mCRPC who have progressed following prior therapy that included a new
hormonal agent (NHA). These approvals were based on the data from the PROfound Phase
III trial.

**AstraZeneca and MSD strategic oncology collaboration**

In July 2017, AstraZeneca and Merck & Co., Inc., Kenilworth, NJ, US, known as MSD
outside the US and Canada, announced a global strategic oncology collaboration to
co-develop and co-commercialise _Lynparza_, the world’s first PARP inhibitor, and
_Koselugo_ (selumetinib), a mitogen-activated protein kinase (MEK) inhibitor, for
multiple cancer types.

Working together, the companies will develop _Lynparza_ and _Koselugo_ and other
potential new medicines as monotherapies. The companies will also develop _Lynparza_
and _Koselugo_ in combination with their respective PD-L1 and PD-1 medicines independently.

Share on:
